NasdaqGS:ACADBiotechs
Is ACADIA Pharmaceuticals (ACAD) A Bargain On Fast Track News And Trial Timing?
ACADIA Pharmaceuticals (ACAD) drew investor attention after the FDA granted Fast Track designation to its investigational drug remlifanserin for hallucinations and delusions in Alzheimer’s disease psychosis, alongside new timing details for the RADIANT trial program.
See our latest analysis for ACADIA Pharmaceuticals.
The Fast Track news arrives after a period where ACADIA Pharmaceuticals’ share price has moved in fits and starts. The 90 day share price return of 11.39% contrasts with a year...